This week we’ll be discussing a Kidney 360 paper validating two recent methods of prognostication of AKI by evaluation of the urine sediment.
Easier to READ full text papers
ISPD Guidelines for PD in Pediatric AKI: the Visual Abstract
Guidelines make for difficult visual abstracts. but Pooja Sanghi does a great job here distilling the essence of them
The ISPD Guidelines for Children with AKI: An Expert Commentary
The Dual Dustat Visual abstracts
UPDATE:
On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.
The Incident dialysis visual abstract has been updated to reflect this change.
At their first attempt, the NSMC interns Alicja Rosolowska and Keia Sanderson have created beautiful visual abstract
The Roxadustat Chronicles: A Two-Article NephJC
Pragmatic trials in nephrology: Bridging the gap between efficacy and effectiveness?
World Kidney Day Chat
Treating Asymptomatic Bacteriuria in Kidney Transplant: the Visual Abstract
The Study at a Glance, visual abstract by Anju Yadav
To Treat or Not to Treat: Bacteriuria in Kidney Transplant Recipients
Announcing #NephTrials
AKI Alerts: the Visual Abstract
Another arresting visual abstract from Denisse Arellano:
Alerting AKI and Avoiding Adverse Aftermaths
STARMEN: the Visual Abstract
Omar Taco with a beautiful VA below
Ponticelli still sparkles in Membranous
The Top Nephrology Stories of 2020
Renalism Returns with Remdesivir
Visual abstract for the Remdesivir in AKI study
Thank-you Dhwanil Patel for the excellent visual abstract for this week’s NephJC Chat
Freely Filtered 28: Fidelio with Burgner and Bakris
The Filtrate welcome Drs. Anna Burgner and George Bakris to discuss the breakthrough clinical trial FIDELIO and the non-steroidal aldosteropne antagonist, finerenone.
Time to vote for the Top Nephrology Stories of 2020
2020 has been quite the year. COVID-19 changed everything… However, 2020 also brought us many important advances in the field of nephrology. In fact, we cannot think of a more impactful year in terms of advances. We have not forgotten about the Top Nephrology Stories of the Year, now in its 11th year.
One of the important parts of the tradition is we depend on the wisdom of the crowd to pick the winner. Pour yourself a nice glass of wine and take some time to pick through these 25 gems and tell us who deserves to be in the top 10.
We need you to vote for your favorites.
Votes will be counted until next Thursday December 31th, 2020
The ballot is here: